Midatech Pharma PLC Appointment of Chief Scientific Officer (9657E)
12 July 2021 - 11:30PM
UK Regulatory
TIDMMTPH
RNS Number : 9657E
Midatech Pharma PLC
12 July 2021
12 July 2021
Midatech Pharma PLC
("Midatech" or the "Company")
Midatech Strengthens Management Team
with
Appointment of Dr Dmitry Zamoryakhin as Chief Scientific
Officer
Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
biodistribution of medicines, announces the appointment of Dr
Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role,
with immediate effect.
Dr Zamoryakhin has broad experience across all phases of
development of drugs and medical devices, working with regulatory
authorities including the EMA, FDA, PMDA, and NMPA. Most recently,
he was Chief Medical Officer of Oxford Biomedica plc (LON: OXB),
having previously held positions of increasing responsibility at
Grunenthal GmbH, Daiichi Sankyo Company Limited (TYO: 4568), Ono
Pharmaceutical Co., Limited (TYO: 4528) and GlaxoSmithKline plc
(LON:GSK, NYSE: GSK). He qualified as a doctor of medicine at Perm
State Medical Academy, Russia, before earning a diploma in
Pharmaceutical Medicine at PHARMED, Universite Libre de Bruxelles,
and an MBA at Warwick Business School.
Dr Zamoryakhin will take over from Steve Damment, EVP R&D
who, after six years with the Company, has decided to retire from
full-time employment at the end of September 2021.
Commenting, Stephen Stamp, CEO and CFO of Midatech said : "I am
delighted to welcome Dmitry to the Midatech team. He is a medic,
was big pharma trained and has been biotech battle hardened. His
breadth of experience will be invaluable as we move our Q-Sphera
programmes and MTX110 through proof of concept to partnering.
"On behalf of everybody at Midatech, I should also like to
express our thanks to Steve Damment for his service to the Company
and, in particular, the key role he has played in championing
MTX110."
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Joint
Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Tel: +44 (0)20 7886 2500
Turner Pope Investments (TPI) Limited (Joint Broker)
Andrew Thacker / James Pope (Corporate Broking)
Tel: +44(0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Maxwell Colbert
Tel: +1 (646) 653 7028
Email: mcolbert@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is a drug delivery technology company focused on improving
the bio-delivery and bio-distribution of medicines. The Company
combines approved and development medications with its proprietary
and innovative drug delivery technologies to provide compelling
products that have the potential to powerfully impact the
lives of patients.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading-edge nanotechnology
used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential
to develop multiple drug assets rather than being reliant
on a limited number of programmes. Midatech's technologies
are supported by 36 patent families including 120 granted
patents and an additional 70 patent applications. Midatech's
headquarters and R&D facility is in Cardiff, UK. For more
information please visit www.midatechpharma.com
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking
statements" within the meaning of legislation in the United
Kingdom and/or United States Private Securities Litigation
Reform Act. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements.
Reference should be made to those documents that Midatech
shall file from time to time or announcements that may be
made by Midatech in accordance with the London Stock Exchange
AIM Rules for Companies ("AIM Rules"), the Disclosure and
Transparency Rules ("DTRs") and the rules and regulations
promulgated by the US Securities and Exchange Commission,
which contains and identifies other important factors that
could cause actual results to differ materially from those
contained in any projections or forward-looking statements.
These forward-looking statements speak only as of the date
of this announcement. All subsequent written and oral forward-looking
statements by or concerning Midatech are expressly qualified
in their entirety by the cautionary statements above. Except
as may be required under the AIM Rules or the DTRs or by relevant
law in the United Kingdom or the United States, Midatech does
not undertake any obligation to publicly update or revise
any forward-looking statements because of new information,
future events or otherwise arising.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUPPMUPGGWP
(END) Dow Jones Newswires
July 12, 2021 09:30 ET (13:30 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024